Logo

Eli Lilly Signs a License and Research Agreement with ProQR to Develop & Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders

Share this

Eli Lilly Signs a License and Research Agreement with ProQR to Develop & Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders

Shots:

  • ProQR to receive $20M up front- $30M as an equity investment & is also eligible to receive ~$1.25B as development- regulatory- and commercialization milestones along with royalties on product sales
  • The companies collaborated to develop editing oligonucleotides for five targets by using ProQR’s Axiomer RNA editing platform
  • ProQR’s Axiomer platform technology enables the editing of single nucleotides in RNA in targeted & specific manner. The technology is designed to recruit endogenous ADAR enzymes to selected target adenosine in a disease-associated RNA

Ref: Globe Newswire | Image: Eli Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions